Dr. Kumar on the Management of Elderly Patients With Multiple Myeloma

Video

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the management of elderly patients with multiple myeloma.

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the management of elderly patients with multiple myeloma.

Myeloma is a disease of older patients, says Kumar, therefore it is extremely important to take into account the patients’ age and potential comorbidities. These might include diabetes and high blood pressure, among others. Such comorbidities could be particularly relevant as they relate to the drugs used to treat patients with this disease. Many of the drugs used in myeloma can have adverse effects on the heart, for example, so oncologists must be aware of these pre-existing conditions before administering certain drugs to their patients.

In addition to drug choices, oncologists also need to consider the dose of these drugs. Given that many of these patients tend to already be on other drugs when they seek treatment for myeloma, drug interactions between these different agents could potentially be dangerous to a patient’s health. They may not be able to metabolize the drugs as well as younger patients do. Some form of dose modification needs to be considered when treating older patients with multiple myeloma. It’s actually safer, says Kumar, to start these patients on a smaller dose, and understand their tolerance, before administering higher doses of the treatment.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute